OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Brian Blaser said the firm has eliminated certain C-suite positions and implemented strategies to improve the firms profitability.

The Netherlands-based firm said that its Aiosyn Mitosis Breast software is used to aid tumor grading and provide a prognostic indicator to guide treatment decisions.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.